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Summary There is ample evidence of the efficacy of cytological screening in the prevention of cervical cancer
but disagreement on the form which screening programmes should take. Simulation models have been used as
a convenient and rapid method of exploring the outcome of different screening policies and of demonstrating
the importance and interrelationships of the variables concerned. However, most such models are either too
abstract or too simplistic to be of practical value in planning screening programmes.
A model is described which reproduces demographic events in a female population (that of England and
Wales) over a 30 year period, and onto this superimposes the natural history of cervical carcinoma, using
data derived from published studies. A microsimulation approach - each individual in the population being
retained as a unit - allows factors such as disease onset and screening uptake to be dependent upon personal
characteristics and past events. Screening can be offered as part of a routine programme, or incidentally - for
example during pregnancy or hospital attendance.
The model allows quantitative evaluation of the complex patterns of screening that are actually observed
and the relative importance of the different components of such screening programmes. Assumptions about
natural history can thus be studied.
Cervical cytology screening is an effective means of
reducing the incidence of invasive cancer of the
cervix (Guzick, 1978; Parkin & Day, 1985).
However, the decision to introduce a screening
programme into a population will depend upon
considerations of the degree of benefit obtainable in
relation to the resources deployed and this ratio will
vary considerably with the actual programme design
(who is to be examined, where, and how often).
The utility of randomised trials to evaluate complex
programmes involving repeated examinations and
follow-up of large numbers of subjects is limited by
the time and expense involved. It is possible to
investigate only a limited number of screening
schedules and the methodology used may be
deemed obsolete or inappropriate by the time
results become available. Finally, the apparently
obvious benefit to be gained from early diagnosis
means that it is difficult to convince physicians and
their patients of the need for a controlled trial, so
that they may be judged unethical, or the control
group receive screening outside the trial.
Health care models are a convenient way of
predicting the results of different interventions,
given varying assumptions about the relationships
involved. Their advantages have been summarised
by Eddy & Schwartz (1982). Simulation models aim
to mimic observed processes as closely as possible,
in the hope that the resulting predictions will be a
guide to future results. Although the assumptions
used and processes modelled have to be stated
explicitly and quantitatively, the availability of
computers means that there is no imperative reason
to seek concise mathematical solutions. The relative
importance of different factors in determining
outcome can be explored and provides an
indication of where further investigations would
provide the most valuable data. Validation can be
carried out by comparing model outputs under
alternative hypotheses to actually observed findings.
Several workers have developed computer
simulation models of cervical cytology screening.
That of Coppleson & Brown (1975) is the simplest,
a Markov process using just 4 states (normal,
dysplasia, carcinoma in situ (c.i.s.) and invasive
cancer) and a set of transition rates between them
compatible with observed cross-sectional data on
incidence and prevalence of the preclinical states
(Bibbo et al., 1971), and cumulative incidence of
clinical cancer (Cutler & Young, 1975). A time-
invariant model using single rates of transition
between states was unable to simulate the observed
data and the solution adopted was to allow each of
the transition rates to vary with age. However,
although the observational data could be used to
estimate certain transition rates (normal to
dysplasia, c.i.s. to cancer), other choices were more
or less arbitrary and a variety of combinations were
capable of reproducing the observed prevalences.
The earliest and most comprehensive simulation
model was that of Knox (1973) which uses up to 26
states in a Markov chain and simulates annual
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transitions between them in a cohort of 10,000
women as they age from 16 to 95. The model is
rather more sophisticated than that of Coppleson
and Brown since it allows transitions between states
to be defined in terms of age or by duration in
initial state. The choice of transition rates to use is
again determined by the need to simulate observed
age-specific prevalence data, and incidence and
mortality of clinical cancer, but within these
constraints the actual rates chosen appear to be
rather arbitrary. Screening is simulated by defining
the ages at which examinations are to be "offered"
during the 95 year lifespan of the cohort and the
percentage attendance (acceptance rate). The model
addresses differential uptake of screening
programmes by making acceptance dependent on
state (reasoning that the risk factors for cervical
cancer, and its precursor conditions, are the same
as those that determine acceptance of screening).
Test characteristics are simulated by specifying the
percentage of the population in the diseased and
normal states who will be deemed positive on
screening.
An identical approach using the same model has
recently been published by a Canadian group (Yu
et al., 1982). They chose to use a rather simplified
natural history, ignoring the existence of
abnormalities preceding in situ cancer; incidence of
the latter was derived by tripling the rates observed
in British Columbia (Boyes et al., 1982), and by
assuming a zero incidence after age 55.
Such models which transfer year by year
specified proportions of a single cohort in a
deterministic fashion have been very useful in
demonstrating the interrelationships between
variables, e.g. between the number of tests offered
per lifetime of a cohort member and the total tests
performed, mortality rate and person-years of life
saved in the entire cohort. The effects of different
acceptance rates and test characteristics on these
outcome measures can be explored. The net cost-
effectiveness of different theoretical screening
policies can be examined by imputing costs to the
different outcomes of screening tests (Blumberg,
1957). Finally, the effect of different theoretical
natural histories on the outcome of screening can
be explored.
There are, however, several disadvantages to the
use of this type of model in providing recom-
mendations for the deployment of resources for
screening. Firstly, in practice, services have to be
planned not for a single cohort over an entire life
span, but for a very heterogenous population over
relatively short time periods. When a screening
programme providing for testing at certain fixed
ages is introduced into a community, only women
younger than the starting age for the screening
policy can possibly receive the full schedule of tests.
Thus, benefits from screening will at first be small,
but increase progressively as more of the
population receives a series of examinations. In
reality, the situation will be more complex, since
many women will have had previous examinations
and the results of a new policy will depend upon
the screening status of the population. This can
neither be simulated by a single cohort model, nor
can the marked differences in the risk of disease in
different birth cohorts, which are evident from an
examination of incidence rates (Hakama, 1982;
Parkin et al., 1985), and which mean that it may be
necessary to change the policy (e.g. ages for
screening) at different time&periods.
Secondly, it may be desirable to use
characteristics other than age to identify subgroups
of the population for "selective screening". Such
policies do not have to be "all or nothing" -
indeed, none of the risk factors which could
reasonably be used have a high enough relative risk
to justify screening only a single group (Hakama et
al., 1979), but they could include more frequent
screening of certain subgroups. Several demo-
graphic variables are associated with increased
disease risk: social class/occupation (Beral, 1974),
marital status (Leck et al., 1978), parity (Miller et
al., 1980). The prevalence and incidence of
precursor lesions are also related to these variables
(Sweetnam et al., 1981; Parkin et al., 1982b). None
of these are directly causative, they are all related
to the underlying confounding variable of
sexual activity. However, from the practical
viewpoint this is of little consequence, provided that
the relevant subgroups are easily identifiable, and a
planning model should be able to explore the
effectiveness of policies involving differential
screening of such subpopulations.
Individual factors also influence attendance at
screening programmes; e.g., age, marital status and
social class, (Sansom et al., 1971; Parkin et al.,
1981). Several studies suggest that non-attenders are
a particularly high risk group, having incidence
rates higher than those expected on the basis of
pre-screening rates (Fidler et al., 1968; Hakama &
Rasanen-Virtanen, 1976). Attendance in future is
often related to past screening history.
Finally, in real life, screening programmes do not
exist in isolation from the rest of the health care
system; the majority of smears are taken
"incidentally", that is at the time of contacts with
health services for other purposes - gynaecology
clinics, family planning services, ante-natal atten-
dances (Parkin et al., 1981; Roberts, 1982). When
screening policies are under consideration such
testing is usually ignored as being "diagnostic"
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symptoms, in particular, are strong predictors of
the existence of dysplasia and carcinoma in situ
(Thomas, 1973; Cooper & Hillier, 1975; Parkin et
al., 1982a), so that the testing of women at hospital
clinics can be considered a form of selective
screening; such subjects are likely to be at high risk
of these conditions by virtue of common
aetiological factors with other gynaecological or
venereal diseases. Attenders of family planning
services will also be at higher than average risk by
being, by definition, a sexually active population; in
addition, oral contraceptives possibly constitute an
independent risk factor (Vessey et al., 1983).
Smears taken on such occasions represent marginal
increments to services being delivered for other
purposes and will have lower costs than those
delivered in special screening clinics. The same is
true for testing in relation to pregnancy. A
planning model should take account of all relevant
screening activity, rather than confining itself to
evaluating unrealistic theoretical policies defined
only in terms of age and interval.
It was the need to develop a practical planning
tool which lead to the development of model
systems able address some of the issues described.
Model structure
A simple single cohort deterministic model based on the
programme written by Knox (1973) has been used as an
ancillary to the main model in order to explore
formulations of natural history in terms of transition rates
between states in a Markov chain. The states defined in
the chain are combinations of pathological condition and
duration; in this way natural histories whose transition
rates are dependent upon their duration, as well as the
individuals age, can be defined. Output from this model is
sets of age-specific prevalences and sojourn time
distributions of the different states. Some examples of
natural histories developed using this model are described
later.
The main model uses a different approach. Because of
the need to make natural history and screening variables
dependent upon characteristics of individuals (such as age,
year of birth, marital status, past history), a
microsimulation approach has been used, where the life
histories of individual members of the population are
modelled. The population used is of arbitrary size, but has
the demographic makeup of that of England and Wales,
and events are studied over a 30 year period (1961-1990).
Each individual in the population is characterised by their
values for a set of variables which will be used in
,Qimulating demographic events, disease natural history or
screening programmes. In practice a minimum of 7
variables has been used (Table I).
The values of these variables for each individual are
updated annually. The data-files for the model consist of
sets of conditional probabilities of transition for each of
these variable values, e.g. the probability of childbirth
(change in value of parity variable) given age, marital
Table I Individual variables used in simulation
Type Name Description
Demographic AGE Age in years
MS Marital status (S; M;W/D)
IP Parity (0=infertile)
Natural history IST Present state (see Fig. 2)
ITIMM Duration (in years) in
present state
LSTAT Previous state
Screening policy ICLOCK Time since previous test
status and initial parity. The model is stochastic in nature
since the occurrence of a transition is decided by
comparing the relevant probability against a randomly
generated number.
The structure of the model is summarised in Figure 1,
and described below. The programme is written in
FORTRAN and consists of some 1870 lines.
Simulation ofdemographic events
The model generates an initial population structure
similar to that of England and Wales in 1961. The choice
of starting population size is arbitrary, but governed by
two considerations (i) the computer time involved in
microsimulation of very large populations and (ii) the
need for reliable results in a stochastic simulation of
relatively rare events. In practice, a population size of
100,000 requires about 3min if of CPU time on a Digital
VAX 11/780 computer for every year of simulation.
Individual members of the starting population are
allocated values for the variables listed in Table I by
reference to a cumulative probability matrix constructed
from census data for England and Wales for 1961,
providing the distribution of the initial population by age,
marital state and parity. This "Assignment" procedure is
not random, so that for a given population size, the
resulting distribution of the population is always the
same. However, the subsequent year by year demographic
events in the "Ageing" procedure (births, marriages and
deaths) are stochastic, individual changes in status are
random within population probabilities, the data sets for
which derive from observed or projected rates of
mortality, nuptiality and fertility for England and Wales.
For mortality, the appropriate probabilities are life table
death rates (e.g. OPCS, 1979). Rates of marriage,
remarriage, widowhood and divorce are available for
individual years since 1961 and can be used to derive
transition probabilities between marital states. Similarly,
data on fertility in England and Wales can be used to
derive probabilities of births given age, marital state and
parity. Projections of rates have to be incorporated if
simulations lasting longer than 20 years (i.e. beyond 1981)
are employed.
Hysterectomy
Women who have had a total hysterectomy are no longer
at risk of disease, this condition is handled by the model554 D.M. PARKIN
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Figure 1 Diagrammatic illustration of the structure of the microsimulation model.
as one of the disease states (see below) since it precludes
the existence of any other state in an individual.
Hysterectomy rates for 5-year age groups have been
calculated from data supplied by OPCS from the Hospital
In-Patient Enquiry (HIPE) for the period of the 1960s and
70s. A similar exercise had been carried out by Alderson
& Donnan (1978) and by extrapolating rates backwards in
time they estimated age-specific prevalence of hysterec-
tomy at different dates. Their estimates of prevalence for
1961 are used in the "Assignment" procedure.
Simulation ofthe disease process
The disease process is simulated by defining a series of
mutually exclusive "states", and the natural history
consists of transfers between these states at rates
dependent upon individual characteristics. The states must
include normal, dead (of causes other than cancer) and
hysterectomy, but otherwise the choice is arbitrary.
Clearly, however, the simpler and closer to reality the
formulation used, the less difficult it is to use
observational data to derive transition rates.SIMULATION MODEL OF SCREENING 555
Figure 2 Natural history: States used in simulation. The arrows represent possible transitions between states.
Figure 2 illustrates the set of states used in the examples
to be described, and the possible transitions between
them.
The "Assignment" procedure (Figure 1) requires that
the individuals in the starting population are allocated to
the disease states according to their age, marital state and
parity. Estimates of the age-specific prevalence of
dysplasia, carcinoma in situ (c.i.s.) and preclinical invasive
disease in unscreened populations are available from
several studies (Dunn & Martin, 1967; Bibbo et al., 1971;
Fidler et al., 1968; Sweetnam et al., 1981; Parkin et al.,
1982b). Prevalence of clinical cancer (women currently
alive who have had a previous diagnosis ofclinical cancer)
must be estimated from incidence of clinical cancer pre-
screening, and survival rates for the same time period.
Appendix A shows a set of estimated age-specific
prevalences of the pre-clinical states, clinical cancer, and
also of hysterectomy. The variation of prevalence of
preinvasive disease by parity and marital state can be
estimated from published data (Sweetnam et al., 1981;
Parkin et al., 1982a).
During the simulation, disease natural history is
modelled in the "Transfer" procedure by the stochastic
transfer of individuals between states according to
probabilities conditional upon age, duration in state,
marital status and parity. Three sets of transition rates
corresponding to different natural histories (HI, H2 and
H3) are reproduced in Appendix B. Figure 3 illustrates
the distribution of sojourn times of pre-invasive states
with these three different natural histories. The total
number of c.i.s. which progress to invasion (proportional
to the shaded area under the lower curves) is the same in
all three, but the distributions are exponential in HI and
H2, and peaked in H3. With HI, the proportion of c.i.s.
which regress is much lower than with the other two
natural histories. In all three, however, dysplasia is a
relatively transient condition; the majority regress, and the
median duration is only 2-3 years.
Simulation ofscreening andfollow-up
There is considerable flexibility in modelling screening
programmes. The "Screening" procedure (Figure 1) is
used to specify policies of "routine" screening, which are
defined by:
1. The years of the simulation routine in which screening
is to be offered.
2. The individuals to be offered screening - defined by
age, marital status, parity and time since previous test.
3. The attendance rate - dependent upon the above, plus
disease state.
4. Test sensitivity (probability of positive test for
individuals in disease states).
5. Test specificity (probability of negative test for normal
individuals).
In addition, since the model follows individuals, it is
possible to simulate contacts with the health care system
and the "incidental" screening which occurs on such
occasions. Examinations during pregnancy are easily
simulated by incorporating screening into the Ageing
subroutine for those individuals in whom childbirth is
deemed to occur. Screening in connection with
gynaecological attendance can also be modelled. There is
good information available on rates of hospital admission,
by age, from the hospital in-patient enquiry (HIPE), but
for gynaecology out-patients only total annual numbers of
attendances (new and old) are recorded (DHSS, 1983).
The annual numbers ofcytology tests from hospital clinics
in England and Wales between 1965 and 1980 (Roberts,
1982) corresponds very closely to the numbers of
gynaecology admissions. For simplicity, therefore, the
model approximates gynaecological testing by using age-
specific in-patient admission rates derived from HIPE for
1966-80 with extrapolations beyond these years based on
an observed annual increase of 2%. For individuals with
pre-clinical lesions (states 2-4) attendance rates are
multiplied by 3 to correspond with the observed relative
prevalence (first smears only) of abnormalities in clinic
attenders compared to other sources of tests (Parkin et al.,
1982a). There is much less information about rates of
attendance for family planning services, although about
1.5 million women attend community clinics each year556 D.M. PARKIN
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Figure 3 Sojourn time distributions of dysplasias (L) and carcinomas in situ (R). Frequency distributions of
the duration of preinvasive states (dysplasia and carcinoma in situ) which are generated during the lifespan
(0-85 years) of a cohort of 100,000 women, with natural histories HI, H2 and H3. The lower curve is for
progressive lesions (dysplasias which become c.i.s.; c.i.s. which become invasive), and the shading below this
curve demonstrates the shape of their sojourn time distribution. The upper curve is for all lesions, and the
unshaded area between the upper and lower curves is the sojourn time distribution of regressive lesions.
(DHSS, 1983) and in 1980 such clinics took 356.000
smears (Roberts, 1982).
Individuals in state 5 (clinical cancer) are not eligible
for screening. Although a cytological smear might in
practice be taken from such women for diagnostic
purposes, these do not constitute screening tests as such,
and so are not incorporated into screening schedules. When
individuals in states 1 to 4 are screened and found to be
positive, they are transferred to a new state "Screened
positive" (state 6). The subsequent treatment of
individuals in this state can be varied to simulate different
follow-up policies and procedures. For example,
individuals in state 6, previous state 1 (normal) are false
positives, and can be returned to state 1 the subsequent
year. In reality, some individuals with screen-detected
disease escape adequate follow-up or treatment (Elwood
et al., 1984); this can be simulated by specifying a set of
transfer probabilities from the positive state (6) to the
original state - perhaps for a limited time after detection.
In the results to be presented, individuals in state 6 are
deemed not to be at risk of death from carcinoma of
cervix. Although this is true for c.i.s. detected by
rogresive 6.5
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screening, for which relative survival is close to 100%
(OPCS, 1980), micro- or occult invasive cancer detected
by screening (state 6, previous state 4) will have a small
excess risk of death. However, since survival rates by
method of detection are not available and in established
programmes asymptomatic screen-detected cases will
almost always be at a very early stage of invasion,
transitions from state 6 to 8 have been ignored for the
sake of simplicity.
Model output
Despite the relative simplicity of the demographic element
of the simulation, the concordance between the age,
marital and parity composition of the simulated
population, and that observed up to 1981 or projected for
the period 1982-1991) for England and Wales is very
close (Figure 4).
It is possible to devise sets of transition rates between
disease states which differ for successive time periods in
order to mimic the cohort changes in disease incidence
that seem to be occuring in England and Wales. In the
examples below, the same set of data have been used for
the entire period 1961-1990; however, when transition
from normal to dysplasia is made dependent upon marital
state and parity, the changing pattern of marriage and
divorce and, to a much lesser extent, childbearing will
result in changing disease rates. Figure 5 shows the
progressive rise in the prevalence of dysplasia and
carcinoma in situ during the period of simulation. At the
beginning of simulation the age-specific incidence curve of
1981
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clinical cancer is close to that observed, as it should be,
since the observed incidence was used in the derivation of
natural history. However, in the absence of screening,
predicted incidence and mortality both show a steady rise
throughout the 30 years of simulation when transition
rates conditional upon age, marital state and parity are
used (Figure 6, curve M), but not when these rates are
related only to age (curve A). In reality a decline in
incidence and mortality is being seen in England and
Wales, although this is almost certainly as a result of the
screening programmes, without which both would have
risen (Parkin et al., 1985).
The number of combinations of natural histories,
screening policies, attendance rates, test characteristics etc.
which can be examined in this population is very large
and only a few examples will be given. The results of
screening are calculated as the difference between the
average values of outcome parameters of interest from
several simulation runs in the presence and absence of
screening. Three outcome parameters have been examined:
the reduction in new cases of clinically diagnosed cancer,
the reduction in the number of deaths from cervix cancer,
and the reduction in life-years lost due to cancer. Life-
years lost are calculated as:
d
(where d=number of deaths, x=age at death, e? =
expectation of life at age x (from current life table
(OPCS, 1979)), and they are assigned to the year in
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Figure 4 Population pyramid for England and Wales (females) Right: Result of simulation; Left: Population
at 1981 Census (OPCS, 1983); parity data from General Household Surveys 1980-1982 (unpublished).558 D.M. PARKIN
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Figure 5 Age-specific prevalence of dysplasia and
carcinoma in situ. The curves represent prevalence at
four different points in time during a simulation, using
natural history H1 (results with H2 and H3 are very
similar). (-) 1961; (---) 1966; (-.-. ) 1976; ( ) 1986.
which the death occurs (so that all potential years of life
lost by women who die during the 30 years of simulation
are summed). These three parameters do not change to
the same degree with different policies; much will depend
upon the ages at which screening is concentrated. The
savings resulting from screening can be presented as
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absolute or percentage reductions from the baseline no-
screening values (the latter allowing a direct comparison
of the effects achieved on the different outcome
parameters).
In order to estimate the cost-effectiveness of different
programmes, the savings achieved must be compared with
the input of the screening programme. The costs of a
programme are likely to be reflected by the actual number
of tests carried out, and by the work involved in the
further examination and treatment of individuals found
"positive" at the screening test. Thus, programme input is
taken as total tests performed, and the number of
"positive" tests during the period of screening, and several
ratios relatinig input to output can be calculated.
Comparison ofdifferent natural histories
Three natural histories (H1, H2, H3) are illustrated in
Appendix B and Figure 3. The actual numbers of cancer
cases, deaths and years of life lost which result from
simulation of a 30 year period when no screening is
carried out vary slightly between the three different
natural histories, thus the comparison of the effects of
screening examines percentage change rather than
absolute numbers. Table II presents the results of two
different screening policies under the assumptions of two
different attendance rates (80%, 50%; probability for all
women equal) and these three natural histories. The first
policy (A) is that originally recommended for England
and Wales (Ministry of Health, 1966): 5-yearly
examinations of women between the ages of 35 and 65.
The second policy (B) is more intensive: 3-yearly
examinations between the ages of 25 and 65, similar to the
maximum frequency suggested by the British Society of
Clinical Cytology (Spriggs & Husain, 1977), and involves
up to 14 tests per lifetime, compared with 7 in policy A.
The results are as expected, with larger savings resulting
from the more intensive policy and higher attendance rate.
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Figure 6 Incidence and mortality rates from cervical carcinoma. (A A) Observed incidence of invasive
carcinoma of cervix; England & Wales, 1962-1980; ( *) Observed mortality from carcinoma of cervix
England and Wales, 1961-1981. (----) M; (--) A. Simulated incidence 1961-1990; ( ) M; ( -) A.
Simulated mortality 1961-1990; (M) disease onset related to marital state and parity; (A) disease onset not
related to marital state and parity.
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Table II Comparison of 3 natural histories
Screening policies: A: Ages 35-65 at 5-year intervals (max=7
per lifetime)
B: Ages 25-65 at 3-year intervals
(max= 14 per lifetime)
Test characteristics: Sensitivity=70% Specificity=99.5%
Attendance: Probability ofattending screening, 80% or
50%, equal for all women
Follow-up: Annual loss to follow up for 3 years after
detection by screening - dysplasia 8%,
c.i.s. 4%
Model input Outcome (1961-1990)
Percentage
Natural Tests % reduction
history Policy Attendance (thousands) pos. Cases Deaths Pyll
50% 121 1.8 42 40 43 A 80% 193 1.7 57 51 52
HI 50% 249 1.7 58 53 59
B 80% 396 1.5 71 63 68
A 50% 121 1.8 39 35 35
80% 193 1.7 54 47 47
H2 B 50% 249 1.6 57 51 56
80% 397 1.5 69 63 67
A 50% 121 1.8 46 39 39
80% 193 1.7 62 54 54
H3 B 50% 250 1.7 63 53 61
80% 395 1.6 77 66 69
However, the increases in savings are not in proportion to
the extra input in terms of numbers of examinations
performed. It also appears that almost the same reduction
in cases and deaths is achieved by increasing attendance in
policy A at the cost of 60% more tests, as by moving to
the more intensive policy B at the same rate of
attendance, when the number of tests more than doubles.
The outcome of screening is not very sensitive to choice of
natural history, the differences between them are not large
and become relatively smaller as intensity of screening
increases. In general, the best results are obtained
assuming natural history H3, and the poorest with H2.
This might be anticipated from the distribution of sojourn
times shown in Figure 3, the median duration of the pre-
clinical detectable phase of invasive lesions is 14.8 years
for H3, 12.4 years for Hl and 9.1 years for H2.
Figure 7 plots the cumulative person-years of life lost
during the 30 years of simulation, using natural histories
HI and H3 both in the absence of screening and with the
policy of 5-yearly examinations (80% attendance rate)
summarised in Table II. The reduction in life-years lost
achieved by screening is not evenly spaced throughout the
30 years. In the first 10 years there is relatively little
effect; thereafter the "saving" increases progressively with
time. This is the kind of result to be expected, since
screening interrupts the disease in the pre-clinical stages -
it is only some years later that some of the individuals so
detected (and successfully treated) would have died from
clinical cancer if screening had not been instituted.
Evaluation of actual screening programmes should make
allowance for this lag time, and to expect an immediate
effect in terms of mortality is unreasonable. Similarly,
some of the benefits of a screening programme, especially
longer term effects on mortality, would accrue after its
cessation. When comparisons of outcome are confined to
the period of screening, some of the observed excess
reduction in cases compared to deaths (as in Table II) will
be due to this effect.
In the following examples illustrating the effects of
different screening policies, a single natural history (H1)
has been used for simplicity.
Comparison ofdifferent patterns ofattendance
Figure 8 shows the numbers of cases, deaths and person-
years of life lost over 30 years, assuming different
attendance rates with a 5-yearly screening policy (as
summarised in Table II). The tendency for the number of
cases, deaths and life-years lost (and in the savings in
these parameters) to reach a plateau indicates that, with a560 D.M. PARKIN
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Figure 7 Cumulative person-years of life lost during
the 30-year simulation period. The upper diagram
presents the results using natural history H1, the lower
using H3. The upper curve shows the potential life-
years lost each year in the absence of screening, the
lower curve is the loss when the population aged 35-65
is screened at 5-year intervals, with an 80% attendance
rate (Policy A, Table II).
schedule of 5-yearly screenings, there will always be a
proportion of clinical cancers which pass through their
pre-invasive stages in less than 5 years. This relationship is
complicated by a less than perfect detection of
abnormalities on screening (70% sensitivity) and the
escape of a small proportion of screen-detected cases from
surveillance. In this simple example, the number of
screening tests carried out in the population is directly
proportional to the attendance rate, so that the ratio of
savings to tests also falls with increasing attendance rates.
However, this decline is less steep for the ratio "savings
per positive test", because the yield of screening
(proportion of tests which are positive) falls as the
intensity of screening increases (from 20 per 1000 at 15%
attendance to 16.3 per 1000 at 90% attendance). This is a
consequence of a reduction in prevalence of preclinical
lesions in the population with an increased intensity of
screening.
The micro-simulation model allows screening
attendance to be made conditional upon personal
variables, some examples are shown in Table III. A
simplistic situation is illustrated by columns 4 and 5,
where, within an overall attendance rate of 60%, the
outcome of screening when the probability of attendance
is the same for all individuals ("random") is compared to
that when 20% of women never attend. The savings when
there is a group of non-attenders are inferior to those
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Figure 8 Results of screening at different rates of
attendance. Natural history - HI. Screening policy -
5-yearly tests aged 35-65 (see Table II). Attendance -
Random, from 0%-90%. (0) life-years lost; (A)
cases; (*) deaths.
obtained when a random 60% of the population attend
for each test, but the programme costs are the same.
Women who do not attend screening programmes appear
to be at higher risk of cervix cancer than the general
population (Fidler et al., 1968; Johanneson et al., 1982).
The second column of Table III represents the case where
screening attendance is only half as likely in women with
abnormalities of the cervix (dysplasia, c.i.s., micro/occult-
invasive cancer) as in normals. The savings compared with
random attendance of all individuals are reduced by about
one quarter There are naturally considerably fewer
positive tests, of which a greater proportion are false-
positives. The overall outcome is a reduction in savings
per 1000 tests, but savings per positive test are scarcely
affected.
In the same table, the effect of making probability of
attendance depend upon marital state is shown. The ratios
chosen are 5:9:2 for single:married:formerly married (the
approximate ratio observed in the Leeds-Wakefield study
of Parkin et al., 1981). The natural history used makes
transitions from normal to dysplasia conditional upon
marital status (the respective relative risks are
1.0. 1.09. 2.46), so that prevalence of precursor conditions
will be highest in the formerly married, and their poorer
attendance results in small reductions in savings and in
positive tests. The ratios ratios savings per 1000 tests and
savings per positive test are slightly below those seen
when a random 80% of women attend for screening.
Attendance for screening examinations tends to
decrease with age. Table III (last column) shows a
simulation of 30 years screening where the rate of
attendance falls from 60% at age 35 to 30% at age 65.
This is compared with a similar overall rate of
n 19
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Table III Effect of non-random attendance
Screening policy:
Attendance:
Test characteristics:
Follow up:
Outcome 1961-1990
Examinations at ages 35, 40, 45, 50, 55, 60, 65
As shown in Table
Sensitivity 70%, Specificity 99.5%
Annual loss to follow up for 3 years after detection by screening - dysplasia 8%,
cis 4%
Natural History HI
Attendance at screening
Overall rate 80% Overall=60% Overall=45%
Attendance
for normal
state= x 2
Random abnormal
Attendance
a marital
state, ratio
S:M: WID
5:9:2
Attendance
20% women cxage
never 60% at 35
Random attend Random 30% at 65
Savings
Cases
Deaths
Life-years
Tests
Total (thousands)
Positive
- of which false pos.
Savings per 1000 tests
Cases
Deaths
Life-years
Savings per positive test
Cases
Deaths
Life-years
430 321
210 159
4233 3324
193 192
3193 2279
30% 42%
2.2 1.7
1.1 0.8
22.0 17.4
0.13 0.14
0.07 0.07
1.39 1.46
393
196
4021
399 352 340 300
195 166 170 128
3725 3167 3469 2751
190 144 145 109 110
3172 2364 2421 1940 2049
29% 28% 30% 25% 26%
2.1
1.0
21.2
2.8 2.4 3.1 2.7
1.4 1.1 1.6 1.2
25.9 21.8 31.9 25.1
0.12 0.17 0.15 0.18 0.15
0.06 0.08 0.07 0.09 0.06
1.27 1.58 1.31 1.79 1.34
examination (45%) at all ages. The savings of cases,
deaths, and life-years are less when screening attendance
falls off with age, even though there is a slightly increased
proportion of positive screening examinations. The
explanation is probably the higher prevalence of precursor
lesions in younger women, so that yield of positives is
higher when attendance is greater at younger ages, but
that this is offset by the more rapid progression of
carcinoma in situ in older women (see Appendix B), so
that failure to interrupt the course of such lesions by
screening has greater consequences in terms of clinical
cancer.
Test characteristics andfollow-up
In any screening programme, not all individuals detected
with precursor lesions will be removed from the risk of
developing clinical cancer. This may be because follow-up
is inadequate (the individuals do not attend for further
screening tests, or for diagnostic biopsy), or because such
follow-up procedures (e.g. regular 6 monthly cytology, or
treatment by laser or cone biopsy) may themselves be
inadequate. In the results so far examined the assumption
was that screen-detected dysplasias (in state 6) escape
surveillance (revert to dysplasia, state 2) at a rate of 8%
per year for 3 years (equivalent to one fifth of the cases
detected). For c.i.s. the loss was only half of this rate
(since it is assumed that the cytological features at
screening would prompt more intensive follow-up of the
case). Table IV examines two other possibilities which
envisage more successful surveillance. As quality of
follow-up deteriorates so do the savings achieved (cases,
lives, life-years), and there is a small increase in the
number of tests carried out (fewer people are successfully
treated or under permanent surveillance) and in the
proportion of screening tests that are positive (since the
prevalence of precursor lesions which are not treated or
under follow-up will increase). Nevertheless, within the
range examined here the differences in savings achieved
and in the ratio ofsavings to tests are rather small.
Screening test performance is defined in terms of
sensitivity and specificity, and these bear a reciprocal
relationship to each other. In the programmes so far
examined a test sensitivity of 70% and specificity of562 D.M. PARKIN
Table IV Effect of test parameters and follow-up intensity
Screening policy: Examinations at ages 35, 40, 45, 50, 55, 60, 65
Attendance: A random 80% of individuals for each test
Test characteristics: As shown in Table heading
Follow up: Annual loss to follow up of cases of dysplasia and cis detected by screening -
as shown in table heading
Outcome 1961-1990 Natural history: HI
% loss tofollow-up
ofscreen-detected cases 0% dysplasia 2% dysplasia 8% dysplasia
(each yearfor 3 years) 0% cis 1% cis 4% cis
70% sensitivity 90% sensitivity 50% sensitivity
Test characteristics 99.5% specificity 99% specificity 99.9% specificity
Savings
Cases 455 442 430 521 373
Deaths 230 223 210 269 163
Life-years 4806 4533 4233 5390 3475
Tests
Total (thousands) 191 192 193 192 193
Positive 3049 3106 3193 4704 1919
- of which false pos. 31% 29% 30% 40% 10%
Savings per 1000 tests
Cases 2.4 2.3 2.2 2.7 1.9
Deaths 1.2 1.2 1.1 1.4 0.8
Life-years 25.2 23.6 22.0 28.1 18.0
Savings per positive test
Cases 0.15 0.14 0.13 0.11 0.19
Deaths 0.08 0.07 0.07 0.06 0.08
Life-years 1.58 1.46 1.33 1.15 1.81
99.5% (5 per 1000 false positive rate) has been assumed,
values approximately equivalent to those estimated from
the results of screening programmes (Husain, 1976; Boyes
et al., 1982). In Table IV two other possibilities are
examined; one envisages a higher sensitivity (90%),
achieved presumably by the classification of minor degrees
of cytological change as "abnormal", with a corres-
ponding decrease in specificity (to 99%), the other has a
specificity of 99.9% snd sensitivity of 50%. Savings in
cases, lives and life-years increase in direct proportion to
the test sensitivity. However, with the concomitant
decrease in specificity, an increasing number of false
positive tests occur. The result is that the ratio of savings
per positive test for the three different sets of test
characteristics are in the opposite direction from the
savings per total tests.
Some selective policies
Table V examines the outcome of some screening policies
where screening offers are dependent upon factors other
than age. Columns 1-3 are the results of the routine 5-
yearly policy previously examined. However, columns 2
and 3 illustrate possible modifications to the policy which
might have been expected to increase efficiency. Not
examining women who are either single or who have had
no children reduces the number of tests required in the 30
years of simulation by 20% (to 151,000), and increases the
proportion of screening tests which are positive (from 16.6
per 1000 to 18.0 per 1000). However, the decreases in
savings of cancer cases, deaths and life-years lost means
that the outcomes to cost ratios are either the same as
(savings per 1000 test) or inferior to (savings per positive
test) those obtained by screening the whole population.
Since dysplasia is assumed to be a rather transient
lesion, the great majority of which regress to normality,
the effect of ignoring screening tests showing minor
degrees of abnormality (consistent with dysplasia) has
been examined. There is a large reduction in positive tests;
however, failure to follow-up dysplasias leads to a
reduction in the savings achieved, so that although the
ratios of savings per positive test are improved, the ratios
of savings per 1000 tests are worse. Whether such a policy
is worthwhile depends on the relative costs imputed to
negative tests and to true and false positives and a
comparison with the benefits obtained.
Columns 4-6 of Table V examine the effects of
"incidental" testing. Pregnancy-related screening (e.g.SIMULATION MODEL OF SCREENING 563
Table V Comparison of simple screening policies
Screening policy:
Attendance:
Test characteristics:
Follow up:
Outcome 1961-1990
As shown in the Table
At routine screening; 80% random
Sensitivity 70%, specificity 99.5%
Annual loss to follow up for 3 years after detection by screening-dysplasia 8%, cis 4%
Natural history HI
Screening policy
1 2 3 4 5 6 7 8 9
Exact ages 35, 40, 45, 50, 55, 60, 65
Attendance rate 80%
Not para 0 Dysplastic Pregnancy Gynaecology
All women not single tests ignored only attendance 4+5 1+4 1+5 1+4+5
Savings
Cases
Deaths
Life-years
Tests
Total (thousands)
Positive
- of which false pos.
Per 1000 tests
Cases
Deaths
Life-years
Savings perpositive test
Cases
Deaths
Life-years
430
210
4233
193
3193
30%
2.2
1.1
22.0
0.13
0.07
1.33
350
171
3724
151
2723
28%
2.3
1.1
24.7
0.13
0.06
1.37
381
173
3463
194
1236
28%
2.0
0.9
17.9
0.30
0.14
2.80
103
33
999
265 279 416 495 520
125 145 219 244 250
3021 3568 4748 4980 5473
88 63 151 280 253 341
1408 2540 3536 4520 4880 5753
31% 12% 22% 31% 26% 29%
1.2
0.4
11.4
4.2
2.0
48.0
1.8 1.5 2.0
1.0 0.8 1.0
23.6 17.0 19.7
1.5
0.7
16.0
0.07 0.10 0.08 0.09 0.10 0.10
0.02 0.05 0.04 0.05 0.05 0.05
0.71 1.19 1.01 1.05 1.00 1.00
antenatal/postnatal attendance) produces rather small
savings, although because of the young age of testing, the
ratio between savings of life-years and deaths is greater
than the routine policies of columns 1-3. Examinations in
association with attendance at gynaecology departments
(column 5) produces a low rate of testing, corresponding
to 20 per 105 annually, but because of the high risk group
examined (prevalence of abnormal states 2-4 is three
times that in the population) the test yield is high (40 per
1000 abnormal) with few false positives. Thus, although
absolute savings are lower than the routine policies of
columns 1-3, the efficiency (savings per 1000 tests) is
considerably greater. The addition of pregnancy testing to
gynaecology examinations (column 6) produces only
marginal gains for a considerable loss of efficiency.
Columns 7-9 examine policies combining incidental and
routine testing.
Discussion
The advantage of the modelling approach in the
evaluation of different screening programmes and
the drawbacks of single cohort deterministic types
of model have been outlined in the introduction. A
group in the Netherlands has addressed the
problems inherent in the single cohort approach by
carrying out multiple simulations for separate
cohorts, and synthesising the results so that
screening in a population similar to that of the
Netherlands could be studied over a 25 year period
(Habbema et al., 1979). However, in order to
surmount the problems of the deterministic model,
they have subsequently developed a micro-
simulation model (Oortmarssen et al., 1981;
Habbema et al., 1983). This model (MISCAN)
shares many features with that described above,
especially in the emphasis on the use of
observational data to define model parameters, and
the ability to make natural history, screening
attendance and outcome dependent upon individual
characteristics. The results of screening are derived
by summating the differences between the life
events of each individual of a single birth cohort in
the presence and absence of screening. The model
described above simulates a randomised controlled564 D.M. PARKIN
trial - comparing the aggregate of all events in
identical "real-life" populations which have been
subjected to different screening strategies. The
drawbacks of the single-cohort simulation are, as
discussed, that results may be difficult to generalise
to a real community - a clear disadvantage if a
model is to be used to assist the planning process.
Further, there are problems in providing suitable
input data, since most of the -observations on
population demography, disease natural history,
screening attendance etc are cross-sectional, and
probably not suitable for application to a single
cohort over a period of 90 years or more.
The "population" component of the model
described is very simplistic and relatively crude in
comparison to a demographer's model for
population projection. Nevertheless, it serves the
function demanded of it in the present context -
maintaining a population which is "realistic" in its
composition (by age, marital status and parity) over
the relatively short time span of the simulation.
The natural history of preclinical carcinoma of
the cervix is a continuum: the extension of cellular
abnormalities to involve the entire thickness of the
cervical epithelium and subsequent invasion, and
progressively increasing cellular atypia. When this is
simulated by a set of discrete "states", it seems
unlikely that rates of transfer between them are
independent of the duration already spent in a state
(the fundamental property of a Markov process).
Such independence would imply that the
distribution of sojourn times of the disease stages
was exponential in form. There is no evidence for
or against this, but it seems prudent to allow for
other possibilities. It was not possible to devise a
natural history compatible with observed prevalence
of preclinical states and incidence of invasive cancer
in which transfer probabilities were independent of
age; in the three versions used the probability of
progression to invasive disease increases in older
women. A variation in the speed of evolution of
pre-clinical carcinoma of the cervix with age has
been proposed from time to time (Lancet, 1981),
and although the biological mechanism underlying
this must be speculative, it could conceivably be
due to differences in the proportions of dysplastic
lesions related to viral infection (Singer et al.,
1984).
The choice of disease states in a model should
correspond to categories familiar in clinical or
pathological studies (so that observed data are
available for use in the model), and also be the
minimum possible, so that the specification of
disease natural history is simplified. There has been
a recent trend to the use of the terminology
"cervical intra-epithelial neoplasia" (C.I.N.) for all
pre-invasive abnormalities of the cervix (Richart &
Barron, 1969; Koss, 1978). However, most
quantitative studies on natural history have used
the dysplasia/carcinoma in-situ terminology and,
despite the dichotomisation of what is clearly a
continuum of pathological change, this terminology
has been retained. The use of two pre-invasive
states has the advantage that the "dysplasia"
category can include minor, often transient
abnormalities, which are detected by screening, and
lead to interruption of the natural history, if only
by causing increasing surveillance of the patient.
It has been the arbitrary choice of natural history
parameters that has made much simulation work
unconvincing (see, for example, Chamberlain,
1982). The specification of natural history has been
based, wherever possible, on data on cross-sectional
prevalence and incidence rates, and on obser-
vational studies of preinvasive disease. Never-
theless, a range of possibilities is still plausible,
although the results of simulation were not very
sensitive to the choice of natural history in the
present study. Further information on sojourn time
distribution of the preclinical detectable phase
could be derived from analysis of screening
histories of women developing invasive cancer (e.g.
Walter & Day, 1983). Further work envisages the
comparison of observed and simulated trends in
age-specific incidence and mortality from cervical
cancer in England and Wales, employing different,
assumptions about natural history, and estimates of
screening activity since 1961.
The potential for simulating complex screening
programmes with a micro-simulation model has
been demonstrated; this includes the ability to
investigate selective screening policies. The
formulation of such policies requires that
individuals with a high relative risk can be easily
identified. For cervix cancer, risk is strongly
associated with the sexual history of the individual
(Rotkin, 1973) or their partner (Skegg et al., 1982),
but these are scarcely practicable variables for
defining a screening policy. Because the demo-
graphic component of the model uses marital status
and parity of individuals, their value (along with
age) as policy-defining factors can easily be studied.
Although theoretically possible to add social class
to this part of the model, simulation of the social
class composition of the female population of
England and Wales and the changes which occur in
the status of individuals with time is not feasible;
furthermore it seems doubtful that specification of
screening policies in such terms would be
acceptable.
The model is also able to examine the effect of
examinations carried out incidental to other health
care contacts. The, existence of such tests is often
ignored when screening programmes are being
planned; however, smears taken at the time of other
contacts with the health care system (e.g. preg-SIMULATION MODEL OF SCREENING 565
nancy. gynaecology attendance, family planning
clinics) are a fairly satisfactory and efficient way of
reaching relatively high risk groups who may
otherwise not attend for screening. A screening
programme should seek to add a set of special
screening examinations to this background service.
In the results presented, relatively simple
measures of output have been compared with
inputs in terms of tests performed, and number of
follow-up examinations (positive tests). It is
possible to refine this approach in many ways.
Benefits of screening could be calculated as
weighted life years saved (giving greater value to
the saving of young lives), to which could be added
a component of benefit related to avoidance of
non-fatal clinical cancers. Similarly, differential
costs could be computed for incidental tests versus
those taken at special screening clinics, and for the
follow-up and treatment of false-positives and true
Appendix A
positives. This has not been done, since the values
and weightings involved would be to some extent
arbitrary, and the examination of all the resulting
combinations would thus become a modelling
exercise in its own right.
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(SCRMOD) from which elements of the models described
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Leeds) and Mr M. Smans (IARC) for assistance with
programming, to Dr A.D. Clayden (University of Leeds)
for assistance with design concepts, and to Dr N.E. Day
(IARC) for advice and natural history data from the
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Appendix B
Starting prevalence ofstates 2-5 and 7
(Per 10,000)
Age-group State
2 3 4 5 7
0-4 0 0 0 0 0
5-9 0 0 0 0 0
10-14 0 0 0 0 0
15-19 40 3 0 0 0
20-24 120 18 0 0 0
25-29 147 49 1 1 6
30-34 130 76 3 2 15
35-39 108 90 5 8 100
40-44 88 88 8 15 250
45-49 67 79 9 20 420
50-54 61 68 10 22 505
55-59 60 58 9 21 525
60-64 59 51 8 20 530
65-69 58 45 8 18 540
70-74 57 40 7 17 545
75-79 56 36 7 14 550
80-84 55 33 7 12 550
85-89 54 30 6 10 550
90-94 53 28 6 10 550
95-99 52 26 6 10 550
States: 2 Dysplasia
3 Carcinoma in situ
4 Occult/micro-invasive cancer
5 Clinical cancer
7 Hysterectomy
Transition rate data, representing three alternative natural
histories, HI, H2 and H3
A full set of transition rates are shown for Hi. Each line
terminates in a transfer rate (% per year) in column 7,
this rate being appropriate for the states, ages, and
durations in the initial 6 columns, the contents of which
are defined in the key. Thus, line 1 gives a rate of transfer
from state 1 to state 2 (see Figure 2 for the codes for each
state), between the ages of 16 and 20, and for durations in
the initial state (1) between 0 and 99 years.
For the sake of brevity, for natural histories H2 and
H3, only transition rates into and out of state 3 (c.i.s.) are
shown.
The incidence of dysplasia (transfer 1 to 2) is derived
from observed data (Dunn & Martin, 1967; Parkin et al.,
1982b), and transition from clinical cancer to death (5 to
8) is derived from age/duration-specific survival rates for
England and Wales (OPCS, 1980). Dysplasia is a
relatively transient condition, and the high regression rates
(2 to 1) used here (12.5-25% per year) are consistent with
observed data (Stern & Neely, 1964; Fox, 1967; Nasiell et
al., 1976). In HI c.i.s. (state 3) is made a relatively stable
condition by specifying low rates of entry from (2 to 3)
and regression to (3 to 2) dysplasia; these are considerably
higher in H2 and H3. In HI and H2 transition from c.i.s.
to preclinical invasive disease (3 to 4) is age-dependent
only, and calculated from age-specific prevalence of c.i.s.
and incidence of clinical cancer in the absence of
screening. Transition rates in H3 are the same as those in
H2, except that progression from c.i.s. is dependent upon
duration. The rate/duration pairs are arbitrary inasmuch
as they are derived so that the observed prevalence of
c.i.s. and incidence of clinical cancer are reproduced by
the model; in practice, this imposes considerable
constraints on the range of values that can be used.
The full data set for the "Transfer" procedure uses
information on relative risk of preclinical disease by
marital condition and parity (Parkin et al., 1982b) to
weight the transfer rates from normality (transitions 1 to
2 in the examples shown).566 D.M. PARKIN
HI
Column
1 2 3 4 5
H2
Column
6 7 1 2 3 4 5
2
2
2
3
3
3
3
3
3
3
3
3
3
3
3
4
4
3
3
3
4
5
5
5
5
S
5
5
5
5
5
5 5
5
5
5
5
5
5
5
2
2
2
2
2
2
2
2
1
3
2
2
4
4
4
4
4
4
4
4
4
4
5
S
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
16
21
26
31
36
41
46
51
16
51
16
16
51
16
21
26
31
36
41
51
61
71
81
16
16
16
16
16
31
31
31
41
41
41
51
51
51
61
61
61
71
71
71
81
81
81
16
20 0
25 0
30 0
35 0
40 0
45 0
50 0
100 0
50 0
100 0
100 0
50 0
100 0
20 0
25 0
30 0
35 0
40 0
50 0
60 0
70 0
80 0
100 0
100 1
100 2
30 1
30 2
30 4
40 1
40 2
40 4
50 1
50 2
50 4
60 1
60 2
60 4
70 1
70 2
70 4
80 1
80 2
80 4
100 1
100 2
100 4
100 6
99
99
99
99
99
99
99
99
99
99
99
99
99
99
99
99
99
99
99
99
99
99
99
1
99
1
3
1
3
1
3
1
3
1
3
1
3
1
3
5
99
0.17
0.50
0.45
0.37 Incidence of
0.31 dysplasia
0.25
0.19
0.12
25.00
12.50
5.0
1.0
0.5
0.5
1.0
1.5
2.0 Conversion
3.0 of CIS
5.0 (a age only)
7.0
8.0
9.0
10.0
0.0
100.0
10.0
4.0
2.0
12.0
5.0
3.0
18.0
8.0
4.0
22.0
12.0 Survival
5.0 rates
27.0
14.0
6.0
41.0
18.0
6.0
55.0
20.0
6.0
2.0
2
2
3
3
3
3
3
3
3
3
3
3
3
3
3
3
2
2
4
4
4
4
4
4
4
4
4
4
16
16
16
61
16
21
26
31
36
41
51
61
71
81
85 0
85 2
60 1
100 1
20 0
25 0
30 0
35 0
40 0
50 0
60 0
70 0
80 0
100 0
99
99
99
99
99
99
99
99
99
99
99
99
99
2.0
10.0
5.0
2.5
0.5
1.0
1.5
2.0
3.0
5.0
7.0
8.0
9.0
10.0
H3
Column
1 2 3 4 5 6 7
2
2
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
2
2
4
4
4
4
4
4
4
4
4
4
4
4
4
16
16
16
51
16
16
16
16
16
16
16
51
51
51
51
51
51
100
100
50
100
50
50
50
50
50
50
50
100
100
100
100
100
100
0
2
1
1
0
3
6
9
12
15
18
0
3
6
9
12
15
99
99
99
2
5
8
11
14
17
99
2
5
8
11
14
99
2.0
10.0
5.0
2.5
0.05
1.0
2.0
4.0
8.0
16.0
32.0
1.0
2.0
4.0
8.0
16.0
32.0
KEY
COL. 1 From state codes for the states
2 To state Jare shown in Fig. 2
3 between
4J ages
5 duration in
6J initial state (col. 1)
7 transfer rate, per 100
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